Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging
Fig 5
In vivo and ex vivo imaging of tumor targeting by 4665 and 58F63Y.
(A) in vivo fluorescence imaging of 4665 and 58F63Y to tumor, (B) ex vivo fluorescence imaging of tumor accumulation and biodistribution, and (C, D) quantification of the fluorescence signals in vivo and ex vivo, respectively. Fluorescence intensity was measured in terms of counts/energy/area and presented as an average (n = 3).